Prestige Consumer Healthcare (NYSE:PBH) Hits New 52-Week Low – Should You Sell?

Posted by George Bondi on Nov 6th, 2026

Prestige Consumer Healthcare Inc. (NYSE:PBH – Get Free Report) reached a new 52-week low during mid-day trading on Friday. The company traded as low as $42.30 and last traded at $42.9660, with a volume of 37,944 shares changing hands. The stock had previously closed at $44.32.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. Zacks Research downgraded shares of Prestige Consumer Healthcare from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 29th. Weiss Ratings reissued a “sell (d+)” rating on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 22nd. One equities research analyst has rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $67.67.

Get Our Latest Research Report on Prestige Consumer Healthcare

Prestige Consumer Healthcare Stock Performance

The stock has a 50 day moving average of $48.34 and a 200 day moving average of $53.88. The company has a quick ratio of 1.99, a current ratio of 3.23 and a debt-to-equity ratio of 1.06. The firm has a market cap of $2.04 billion, a price-to-earnings ratio of 12.06, a P/E/G ratio of 1.67 and a beta of 0.30.

Prestige Consumer Healthcare (NYSE:PBH – Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The company reported $1.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.07 by $0.06. The business had revenue of $336.31 million for the quarter, compared to analysts’ expectations of $329.14 million. Prestige Consumer Healthcare had a net margin of 15.57% and a return on equity of 11.39%. The firm’s quarterly revenue was up 22.7% compared to the same quarter last year. During the same period last year, the firm posted $1.07 earnings per share. As a group, analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.56 EPS for the current fiscal year.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. purchased a new position in shares of Prestige Consumer Healthcare during the 2nd quarter valued at $370,187,000. Rice Hall James & Associates LLC bought a new stake in Prestige Consumer Healthcare during the second quarter valued at $32,602,000. The Manufacturers Life Insurance Company purchased a new position in Prestige Consumer Healthcare during the second quarter worth about $31,135,000. Bank of America Corp DE purchased a new position in Prestige Consumer Healthcare during the second quarter worth about $26,277,000. Finally, Bank of New York Mellon Corp bought a new position in Prestige Consumer Healthcare in the 2nd quarter worth about $15,376,000. Institutional investors own 99.95% of the company’s stock.

About Prestige Consumer Healthcare

(Get Free Report)

Prestige Consumer Healthcare Inc (NYSE: PBH) is a consumer healthcare company that develops, acquires, markets and distributes over-the-counter health and wellness products. Its portfolio is focused on established brands designed to address everyday healthcare needs, including digestive health, eye and ear care, oral care, pain relief, cold and allergy symptoms, feminine care and dermatological conditions.

The company’s brands include Dramamine and Bonine for motion-sickness relief; BC and Goody’s for pain relief; Clear Eyes and Murine for eye and ear care; Chloraseptic for sore-throat relief; Compound W for wart removal; Fleet for gastrointestinal health; and Summer’s Eve for feminine care.